IP Overview – “Monoclonal Antibodies against digestive system cancers” Patent Landscape 2010

• Publication date: September 2010

In order to fight digestive system cancers, monoclonal antibody-based therapies have recently reinforced the range of already marketed treatments (mostly constituted of small molecules) and are generating important revenues. Four antibodies have already been approved but new ones are still needed. Many players are therefore trying to position themselves on this sector. This has resulted in an active patent policy that has nevertheless reached a p...

In order to fight digestive system cancers, monoclonal antibody-based therapies have recently reinforced the range of already marketed treatments (mostly constituted of small molecules) and are generating important revenues. Four antibodies have already been approved but new ones are still needed. Many players are therefore trying to position themselves on this sector. This has resulted in an active patent policy that has nevertheless reached a plateau since 2005.

The present report analyses the patent environment and highlights the various monoclonal antibodies that have been developed to diagnose and treat oesophageal, gastric, bile duct, gastro-intestinal, colorectal, hepatic, pancreatic and anal cancers. The major trend is the development of human immunoconjugates against colorectal cancers by targeting growth factor receptors. Although this sector is surrounded by Roche and its subsidiaries, other players, and especially big pharma and biotech companies, continue to develop antibodies targeting new antigens and/or having new properties.

In this competitive sector driven by an important market and where 3000 patent families have been filed, this study « IP Overview – Monoclonal antibodies against digestive system cancers» provides you with a comprehensive panorama of the intellectual property landscape and helps you:

- Position your company’s R&D and IP Portfolio
- Identify key inventors and key players involved in the development of new monoclonal antibodies
- Understand the collaboration networks and their dynamics
- Discover new trends and emerging topics

Please note that a three months access to the full patent database is also included

Biological Therapy Industry

Table of contents

Brief outline of the technology

Generalities

Brief outline of the market - 2009
Patent query
Brief outline of the pipeline - 2010
Evolution of patent filings (1988-2008)
Evolution of the number of applicants
Industrial & institutional filings over time
Map of extensions
Map and evolution of priority filings

Evolution and location of patent filings

Main applicants on the entire period (1988-2008)
Part of the portfolio hold by the first 10 applicants
Breakdown of filings of the main industrial/institutional applicants over time
Main applicants in the last 4 years (2005-2008)
Main co-filings between applicants

Analysis of patent applicants

Analysis of inventors
List of the main inventors
Main research teams
Emerging inventors

Topics of patent filings

Breakdown of the portfolio (for each breakdown is presented the evolution of filings
and the positioning of institutional applicants, industrial applicants and inventors)
1/Type of monoclonal antibodies
2/Targets of monoclonal antibodies
2.1/Growth factor receptors
2.2/Molecules involved in cell adhesion
2.3/Other targets
3/Type of digestive system cancers targeted by mAbs

Focus on ROCHE

Organization chart
Distribution and evolution of patent filings by subsidiaries
Filing policy
Topics of patent applications
Comments

Citation & Extension Analysis

List of the most cited patents and patent applications
Positioning of patent applications portfolio via citation analysis
Most extended patents
Coverage rate classification

Conclusion

Appendices
mAbs clinical trials by company
Applicants/Affiliates